<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2751">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01490190</url>
  </required_header>
  <id_info>
    <org_study_id>P07733</org_study_id>
    <secondary_id>CTRI/2011/11/002098</secondary_id>
    <nct_id>NCT01490190</nct_id>
  </id_info>
  <brief_title>Study of the Use of a Contraceptive Vaginal Ring (NuvaRing) in Normal Daily Practice in Indian Women (P07733)</brief_title>
  <official_title>Contraceptive Vaginal Ring Releasing Etonogestrel and Ethinylestradiol (NuvaRing): Cycle Control, Acceptability and Tolerability Study in Indian Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>India: Drugs Controller General of India</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will collect information on cycle control, acceptability and tolerability of the
      vaginal contraceptive ring (NuvaRing) as used in normal daily practice by Indian women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Participants With Regular Menstrual Cycles</measure>
    <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants who experienced regular menstrual bleeding patterns throughout the period of NuvaRing use. Bleeding patterns were to be characterized by particpants as regular or irregular.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Number of Bleeding Days Per Cycle</measure>
    <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean duration of menstruation, per day, per cycle, during the study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Number of Pads Used Per Day, Per Cycle, During Menstruation While Using Ring</measure>
    <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Intensity of menstruation, as indicated by the median number of pads used per day by participants during each cycle of NuvaRing use.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Intermenstrual Bleeding/Spotting</measure>
    <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of participants who experienced vaginal bleeding, which includes BLEEDING or SPOTTING, at any time during a cycle other than normal menstruation while in the study. Vaginal bleeding that required &gt;=2 pads per day was classified as BLEEDING. Vaginal bleeding that required &lt;=1 pad per day was classified as SPOTTING.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Bleeding Days Per Cycle</measure>
    <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Intermenstrual vaginal bleeding that required &gt;=2 pads per day was classified as BLEEDING.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Spotting Days Per Cycle</measure>
    <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Intermenstrual vaginal bleeding that required &lt;=1 pad per day was classified as SPOTTING.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants' Assessment of Ease of Insertion of Vaginal Ring</measure>
    <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants were asked to classify their ability to insert the NuvaRing as very easy, easy, neutral, difficult, very difficult, or failed. The number of participants who responded to each category was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants' Assessment of Ease of Removal of Vaginal Ring</measure>
    <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants were asked to classify their ability to remove the NuvaRing as very easy, easy, neutral, difficult, very difficult, or failed. The number of participants who responded to each category was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants' Assessment of Feeling Vaginal Ring at Any Time</measure>
    <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants were asked to assess whether they could feel the NuvaRing at any time and to characterize how often as one of the following: never, rarely, occasionally, mostly, or always. The number of participants who responded to each category was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants' Assessment of Feeling Vaginal Ring During Intercourse</measure>
    <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants were asked to assess whether they could feel the NuvaRing during intercourse and to characterize how often as one the following: never, rarely, occasionally, mostly, or always. The number of participants who responded to each category was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Partner Feeling Vaginal Ring During Intercourse</measure>
    <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants were asked if their partners could feel the NuvaRing during intercourse and to characterize their partners' experience as one of the following: never, rarely, occasionally, mostly, or always. The number of participants who responded to each category was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Partner Objecting to Vaginal Ring Use</measure>
    <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants were asked if their partners objected to their using the NuvaRing during intercourse and to characterize the frequency of their partners' objections as one of the following: never, rarely, occasionally, mostly, or always. The number of participants who responded to each category was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants' Overall Satisfaction With Vaginal Ring</measure>
    <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants were asked to characterize their overall satisfaction with the NuvaRing as one of the following: very satisfied, satisfied, neutral, unsatisfied, or very unsatisfied. The number of participants who responded to each category was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Plan to Continue Using Vaginal Ring</measure>
    <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants were asked at follow-up visits after every cycle whether they planned to continue using NuvaRing, and their answers were recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Would Recommend Vaginal Ring to Others</measure>
    <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants were asked at follow-up visits after every cycle whether they would recommend NuvaRing to other women, and their answers were reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Pregnancies Due to Contraceptive Method Failure During the Study</measure>
    <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
    <safety_issue>No</safety_issue>
    <description>For participants with suspected pregnancy during in-treatment period, pregnancy was to be confirmed by hCG qualitative analysis using strip and/or other test(s) at the discretion of the treating physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Reported at Least One Adverse Event During the Study</measure>
    <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product, biologic, or medical device, which does not necessarily have a causal relationship with the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Reported a Serious Adverse Event During the Study</measure>
    <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A serious adverse event is any adverse drug or biologic or device experience that results in death, a life-threatening adverse event, persistent or significant disability or incapacity; requires in-patient hospitalization, or prolonged hospitalization; or causes a congenital anomaly or birth defect.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">252</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>NuvaRing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing)</intervention_name>
    <description>Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.</description>
    <arm_group_label>NuvaRing</arm_group_label>
    <other_name>NuvaRing</other_name>
    <other_name>SCH 900702</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women at risk of pregnancy and seeking contraception

        Exclusion Criteria:

        Exclusion criteria based on approved prescribing information in India:

          -  Presence or history of venous thrombosis, with or without pulmonary embolism.

          -  Presence or history of arterial thrombosis (e.g. cerebrovascular accident, myocardial
             infarction) or prodromi of a thrombosis (e.g. angina pectoris or

        transient ischemic attack).

          -  Known predisposition for venous or arterial thrombosis, with or without hereditary
             involvement such as Activated Protein C (APC) resistance, antithrombin-III
             deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinemia and
             antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant).

          -  History of migraine with focal neurological symptoms.

          -  Diabetes mellitus with vascular involvement.

          -  The presence of a severe or multiple risk factor(s) for venous or arterial thrombosis
             (at the discretion of the doctors)

          -  Pancreatitis or a history thereof if associated with severe hypertriglyceridemia.

          -  Presence or history of severe hepatic disease as long as liver function values have
             not returned to normal.

          -  Presence or history of liver tumors (benign or malignant).

          -  Known or suspected malignant conditions of the genital organs or the breasts, if sex
             steroid-influenced.

          -  Undiagnosed vaginal bleeding.

          -  Known or suspected pregnancy.

          -  Hypersensitivity to the active substances or to any of the excipients of NuvaRing.

          -  Women who are breast feeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MSD Pharmaceuticals Private Ltd.</name>
      <address>
        <city>Gurgaon</city>
        <zip>122002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 8, 2015</lastchanged_date>
  <firstreceived_date>November 22, 2011</firstreceived_date>
  <firstreceived_results_date>November 25, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>3-keto-desogestrel</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NuvaRing: Safety Population</title>
          <description>Safety Population, which included all participants who met inclusion and exclusion criteria and who inserted NuvaRing at least once during the study period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="252"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relocation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inconvenience</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ring expulsion</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NuvaRing: Safety Population</title>
          <description>Safety Population, which included all participants who met inclusion and exclusion criteria and who inserted NuvaRing at least once during the study period.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="252"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Age data were only available for 218 participants.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29.5" spread="5.32"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="252"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Regular Menstrual Cycles</title>
        <description>The number of participants who experienced regular menstrual bleeding patterns throughout the period of NuvaRing use. Bleeding patterns were to be characterized by particpants as regular or irregular.</description>
        <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol Population, which included all participants who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>NuvaRing</title>
            <description>Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="204"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Regular Menstrual Cycles</title>
            <description>The number of participants who experienced regular menstrual bleeding patterns throughout the period of NuvaRing use. Bleeding patterns were to be characterized by particpants as regular or irregular.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>First cycle: Regular</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="192"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Irregular</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Missing data</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Regular</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="199"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Irregular</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Missing data</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Regular</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="200"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Irregular</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Missing data</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Number of Bleeding Days Per Cycle</title>
        <description>Mean duration of menstruation, per day, per cycle, during the study period.</description>
        <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol Population, which included all participants who completed the study as per protocol. Of the total Per Protocol Population (N = 204), data for this outcome measure were missing for 3 partcipants in the first cycle, 1 participant in the second cycle, and 1 participant in the third cycle.</population>
        <group_list>
          <group group_id="O1">
            <title>NuvaRing</title>
            <description>Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="203"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Average Number of Bleeding Days Per Cycle</title>
            <description>Mean duration of menstruation, per day, per cycle, during the study period.</description>
            <units>Days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>First cycle (N = 201)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.8" spread="1.24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle (N = 203)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.7" spread="1.13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle (N = 203)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.6" spread="0.98"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Number of Pads Used Per Day, Per Cycle, During Menstruation While Using Ring</title>
        <description>Intensity of menstruation, as indicated by the median number of pads used per day by participants during each cycle of NuvaRing use.</description>
        <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol Population, which included all participants who completed the study as per protocol. Of the total Per Protocol Population (N = 204), data for this outcome measure were missing for 3 partcipants in the first cycle, 1 participant in the second cycle, and 1 participant in the third cycle.</population>
        <group_list>
          <group group_id="O1">
            <title>NuvaRing</title>
            <description>Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="203"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Average Number of Pads Used Per Day, Per Cycle, During Menstruation While Using Ring</title>
            <description>Intensity of menstruation, as indicated by the median number of pads used per day by participants during each cycle of NuvaRing use.</description>
            <units>Pads</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>First cycle (N = 201)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2" lower_limit="0" upper_limit="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle (N = 203)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2" lower_limit="1" upper_limit="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle (N = 203)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2" lower_limit="1" upper_limit="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Intermenstrual Bleeding/Spotting</title>
        <description>Number of participants who experienced vaginal bleeding, which includes BLEEDING or SPOTTING, at any time during a cycle other than normal menstruation while in the study. Vaginal bleeding that required &gt;=2 pads per day was classified as BLEEDING. Vaginal bleeding that required &lt;=1 pad per day was classified as SPOTTING.</description>
        <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol Population, which included all participants who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>NuvaRing</title>
            <description>Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="204"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Intermenstrual Bleeding/Spotting</title>
            <description>Number of participants who experienced vaginal bleeding, which includes BLEEDING or SPOTTING, at any time during a cycle other than normal menstruation while in the study. Vaginal bleeding that required &gt;=2 pads per day was classified as BLEEDING. Vaginal bleeding that required &lt;=1 pad per day was classified as SPOTTING.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>First cycle: Total bleeding/spotting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Bleeding</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Spotting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Total bleeding/spotting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Bleeding</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Spotting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Total bleeding/spotting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Bleeding</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Spotting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Bleeding Days Per Cycle</title>
        <description>Intermenstrual vaginal bleeding that required &gt;=2 pads per day was classified as BLEEDING.</description>
        <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
        <safety_issue>No</safety_issue>
        <population>One participant in Per Protocol Population who experienced vaginal bleeding was evaluated for duration of bleeding.</population>
        <group_list>
          <group group_id="O1">
            <title>NuvaRing</title>
            <description>Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Bleeding Days Per Cycle</title>
            <description>Intermenstrual vaginal bleeding that required &gt;=2 pads per day was classified as BLEEDING.</description>
            <units>Days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>First cycle</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4" spread="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0" spread="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0" spread="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Spotting Days Per Cycle</title>
        <description>Intermenstrual vaginal bleeding that required &lt;=1 pad per day was classified as SPOTTING.</description>
        <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants in the Per Protocol Population who experienced spotting were evaluated for duration of spotting.</population>
        <group_list>
          <group group_id="O1">
            <title>NuvaRing</title>
            <description>Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Spotting Days Per Cycle</title>
            <description>Intermenstrual vaginal bleeding that required &lt;=1 pad per day was classified as SPOTTING.</description>
            <units>Days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>First cycle (N = 4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.5" spread="4.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle (N = 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0" spread="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle (N = 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3" spread="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants' Assessment of Ease of Insertion of Vaginal Ring</title>
        <description>Participants were asked to classify their ability to insert the NuvaRing as very easy, easy, neutral, difficult, very difficult, or failed. The number of participants who responded to each category was reported.</description>
        <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol Population, which included all participants who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>NuvaRing</title>
            <description>Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="204"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants' Assessment of Ease of Insertion of Vaginal Ring</title>
            <description>Participants were asked to classify their ability to insert the NuvaRing as very easy, easy, neutral, difficult, very difficult, or failed. The number of participants who responded to each category was reported.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>First cycle: Very easy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Easy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="82"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Neutral</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Difficult</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Very difficult</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Failed</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Very easy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="73"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Easy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Neutral</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Difficult</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Very difficult</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Failed</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Very easy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="78"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Easy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="113"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Neutral</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Difficult</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Very difficult</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Failed</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants' Assessment of Ease of Removal of Vaginal Ring</title>
        <description>Participants were asked to classify their ability to remove the NuvaRing as very easy, easy, neutral, difficult, very difficult, or failed. The number of participants who responded to each category was reported.</description>
        <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol Population, which included all participants who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>NuvaRing</title>
            <description>Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="204"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants' Assessment of Ease of Removal of Vaginal Ring</title>
            <description>Participants were asked to classify their ability to remove the NuvaRing as very easy, easy, neutral, difficult, very difficult, or failed. The number of participants who responded to each category was reported.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>First cycle: Very easy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="70"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Easy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="128"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Neutral</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Difficult</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Very difficult</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Failed</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Very easy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Easy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="119"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Neutral</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Difficult</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Very difficult</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Failed</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Very easy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="88"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Easy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="113"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Neutral</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Difficult</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Very different</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Failed</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants' Assessment of Feeling Vaginal Ring at Any Time</title>
        <description>Participants were asked to assess whether they could feel the NuvaRing at any time and to characterize how often as one of the following: never, rarely, occasionally, mostly, or always. The number of participants who responded to each category was reported.</description>
        <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol Population, which included all participants who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>NuvaRing</title>
            <description>Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="204"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants' Assessment of Feeling Vaginal Ring at Any Time</title>
            <description>Participants were asked to assess whether they could feel the NuvaRing at any time and to characterize how often as one of the following: never, rarely, occasionally, mostly, or always. The number of participants who responded to each category was reported.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>First cycle: Never</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="87"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Rarely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="89"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Occasionally</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Mostly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Always</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Never</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="107"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Rarely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Occasionally</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Mostly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Always</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Never</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="117"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Rarely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="79"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Occasionally</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Mostly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Always</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants' Assessment of Feeling Vaginal Ring During Intercourse</title>
        <description>Participants were asked to assess whether they could feel the NuvaRing during intercourse and to characterize how often as one the following: never, rarely, occasionally, mostly, or always. The number of participants who responded to each category was reported.</description>
        <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol Population, which included all participants who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>NuvaRing</title>
            <description>Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="204"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants' Assessment of Feeling Vaginal Ring During Intercourse</title>
            <description>Participants were asked to assess whether they could feel the NuvaRing during intercourse and to characterize how often as one the following: never, rarely, occasionally, mostly, or always. The number of participants who responded to each category was reported.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>First cycle: Never</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="85"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Rarely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Occasionally</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Mostly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Always</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Never</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Rarely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="82"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Occasionally</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Mostly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Always</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Never</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="125"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Rarely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Occasionally</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Mostly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Always</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Partner Feeling Vaginal Ring During Intercourse</title>
        <description>Participants were asked if their partners could feel the NuvaRing during intercourse and to characterize their partners' experience as one of the following: never, rarely, occasionally, mostly, or always. The number of participants who responded to each category was reported.</description>
        <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol Population, which included all participants who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>NuvaRing</title>
            <description>Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="204"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Frequency of Partner Feeling Vaginal Ring During Intercourse</title>
            <description>Participants were asked if their partners could feel the NuvaRing during intercourse and to characterize their partners' experience as one of the following: never, rarely, occasionally, mostly, or always. The number of participants who responded to each category was reported.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>First cycle: Never</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="88"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Rarely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Occasionally</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Mostly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Always</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Never</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="112"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Rarely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="65"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Occasionally</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Mostly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Always</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Never</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="121"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Rarely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Occasionally</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Mostly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Always</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Partner Objecting to Vaginal Ring Use</title>
        <description>Participants were asked if their partners objected to their using the NuvaRing during intercourse and to characterize the frequency of their partners' objections as one of the following: never, rarely, occasionally, mostly, or always. The number of participants who responded to each category was reported.</description>
        <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol Population, which included all participants who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>NuvaRing</title>
            <description>Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="204"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Frequency of Partner Objecting to Vaginal Ring Use</title>
            <description>Participants were asked if their partners objected to their using the NuvaRing during intercourse and to characterize the frequency of their partners' objections as one of the following: never, rarely, occasionally, mostly, or always. The number of participants who responded to each category was reported.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>First cycle: Never</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="129"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Rarely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="70"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Occasionally</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Mostly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle: Always</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Never</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="143"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Rarely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="55"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Occasionally</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Mostly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle: Always</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Never</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="153"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Rarely</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Occasionally</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Mostly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle: Always</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants' Overall Satisfaction With Vaginal Ring</title>
        <description>Participants were asked to characterize their overall satisfaction with the NuvaRing as one of the following: very satisfied, satisfied, neutral, unsatisfied, or very unsatisfied. The number of participants who responded to each category was reported.</description>
        <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population, which included all participants who met inclusion and exclusion criteria and who inserted NuvaRing at least once during the study period.</population>
        <group_list>
          <group group_id="O1">
            <title>NuvaRing</title>
            <description>Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="252"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants' Overall Satisfaction With Vaginal Ring</title>
            <description>Participants were asked to characterize their overall satisfaction with the NuvaRing as one of the following: very satisfied, satisfied, neutral, unsatisfied, or very unsatisfied. The number of participants who responded to each category was reported.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>First cycle (N = 252): Very satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="68"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle (N = 252): Satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="119"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle (N = 252): Neutral</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle (N = 252): Unsatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle (N = 252): Very unsatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle (N = 252): Missing data</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle (N = 213): Very satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="82"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle (N = 213): Satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="112"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle(N = 213): Neutral</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle (N = 213): Unsatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle (N = 213): Very unsatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle (N = 213): Missing data</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle (N = 207): Very satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="88"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle (N = 207): Satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="107"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle (N = 207): Neutral</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle (N = 207): Unsatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle (N = 207): Very unsatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle (N = 207): Missing data</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Plan to Continue Using Vaginal Ring</title>
        <description>Participants were asked at follow-up visits after every cycle whether they planned to continue using NuvaRing, and their answers were recorded.</description>
        <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population, which included all participants who met inclusion and exclusion criteria and who inserted NuvaRing at least once during the study period.</population>
        <group_list>
          <group group_id="O1">
            <title>NuvaRing</title>
            <description>Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="252"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Who Plan to Continue Using Vaginal Ring</title>
            <description>Participants were asked at follow-up visits after every cycle whether they planned to continue using NuvaRing, and their answers were recorded.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>First cycle (N = 252): Yes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="216"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle (N = 252): No</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle (N = 252): Missing data</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle (N = 213): Yes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="205"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle (N = 213): No</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle (N = 213): Missing data</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle (N = 207): Yes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="159"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle (N = 207): No</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle (N = 207): Missing data</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Would Recommend Vaginal Ring to Others</title>
        <description>Participants were asked at follow-up visits after every cycle whether they would recommend NuvaRing to other women, and their answers were reported.</description>
        <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population, which included all participants who met inclusion and exclusion criteria and who inserted NuvaRing at least once during the study period.</population>
        <group_list>
          <group group_id="O1">
            <title>NuvaRing</title>
            <description>Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="252"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Who Would Recommend Vaginal Ring to Others</title>
            <description>Participants were asked at follow-up visits after every cycle whether they would recommend NuvaRing to other women, and their answers were reported.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>First cycle (N = 252): Yes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="208"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle (N = 252): No</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle (N = 252): Missing data</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle (N = 213): Yes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="197"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle (N = 213): No</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle (N = 213): Missing data</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle (N = 207): Yes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="193"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle (N = 207): No</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle (N = 207): Missing data</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Pregnancies Due to Contraceptive Method Failure During the Study</title>
        <description>For participants with suspected pregnancy during in-treatment period, pregnancy was to be confirmed by hCG qualitative analysis using strip and/or other test(s) at the discretion of the treating physician.</description>
        <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population, which included all participants who met inclusion and exclusion criteria and who inserted NuvaRing at least once during the study period.</population>
        <group_list>
          <group group_id="O1">
            <title>NuvaRing</title>
            <description>Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="252"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Pregnancies Due to Contraceptive Method Failure During the Study</title>
            <description>For participants with suspected pregnancy during in-treatment period, pregnancy was to be confirmed by hCG qualitative analysis using strip and/or other test(s) at the discretion of the treating physician.</description>
            <units>Pregnancies</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>First cycle (N = 252): Yes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle (N = 252): No</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="226"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First cycle (N = 252): Missing data</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle (N = 213): Yes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle (N = 213): No</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="210"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second cycle (N = 213): Missing data</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle (N = 207): Yes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle (N = 207): No</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="207"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Third cycle (N = 207): Missing data</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Reported at Least One Adverse Event During the Study</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product, biologic, or medical device, which does not necessarily have a causal relationship with the treatment.</description>
        <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety Population, which included all participants who met inclusion and exclusion criteria and who inserted NuvaRing at least once during the study period.</population>
        <group_list>
          <group group_id="O1">
            <title>NuvaRing</title>
            <description>Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="252"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Who Reported at Least One Adverse Event During the Study</title>
            <description>An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product, biologic, or medical device, which does not necessarily have a causal relationship with the treatment.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Reported a Serious Adverse Event During the Study</title>
        <description>A serious adverse event is any adverse drug or biologic or device experience that results in death, a life-threatening adverse event, persistent or significant disability or incapacity; requires in-patient hospitalization, or prolonged hospitalization; or causes a congenital anomaly or birth defect.</description>
        <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety Population, which included all participants who met inclusion and exclusion criteria and who inserted NuvaRing at least once during the study period.</population>
        <group_list>
          <group group_id="O1">
            <title>NuvaRing</title>
            <description>Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="252"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Who Reported a Serious Adverse Event During the Study</title>
            <description>A serious adverse event is any adverse drug or biologic or device experience that results in death, a life-threatening adverse event, persistent or significant disability or incapacity; requires in-patient hospitalization, or prolonged hospitalization; or causes a congenital anomaly or birth defect.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 84 days (three 28-day cycles)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NuvaRing: Safety Population</title>
          <description>Safety Population, which included all participants who met inclusion and exclusion criteria and who inserted NuvaRing at least once during the study period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The principal investigator agrees not to publish or publicly present interim results of the Study without prior written consent of sponsor, agrees to provide 45 days written notice to sponsor prior to submission for publication or presentation, and permits sponsor to review copies of abstracts and manuscripts for publication, and slides and text of oral presentations and text of any electronically transmitted media such as the Internet, World Wide Web, etc.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
